CC

My thoughts on the conference call-

Good chance we get a grant from the American Association of OPMD.
Take OPMD through phase one human trials then find a partner.
Head & Neck program has lot's of promise in terms of what they learn from the data can be used for other rare cancer targets. (sounds like more Nant/ Benitec partnered programs
AMD - will likely be shelved.
HBV-Still being shopped around..
Instead of a replacement for cliff they are going to contract each program out to consulting firms who have skills for the different programs.
David Suhy said the silence & replace vector was very well received by all the regulatory agencies they spoke to regarding OPMD.